<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mes</journal-id><journal-title-group><journal-title xml:lang="ru">Экстремальная биомедицина</journal-title><trans-title-group xml:lang="en"><trans-title>Extreme Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3033-8964</issn><issn pub-type="epub">3033-8972</issn><publisher><publisher-name>Centre for Strategic Planning of the Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47183/mes.2025-306</article-id><article-id custom-type="elpub" pub-id-type="custom">mes-306</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЕМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>НEMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Определение предикторов неблагоприятного исхода заболевания у пациентов с COVID-19 на основании исследования системы гемостаза</article-title><trans-title-group xml:lang="en"><trans-title>Determination of predictors of adverse disease outcome in patients with COVID-19 based on hemostasis system analysis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2728-6590</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Матвиенко</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Matvienko</surname><given-names>O. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Матвиенко Олеся Юрьевна - канд. мед. наук</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olesia U. Matvienko</p><p>St. Petersburg</p></bio><email xlink:type="simple">matolesya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5060-5102</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Ольга Анатольевна - канд. мед. наук</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga A. Smirnova</p><p>St. Petersburg</p></bio><email xlink:type="simple">olasova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8532-8958</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Головина</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovina</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Головина Ольга Георгиевна - канд. биол. наук</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga G. Golovina</p><p>St. Petersburg</p></bio><email xlink:type="simple">olga.golovina.48@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Research Institute of Hematology and Transfusiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2025</year></pub-date><volume>27</volume><issue>4</issue><fpage>587</fpage><lpage>593</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Матвиенко О.Ю., Смирнова О.А., Головина О.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Матвиенко О.Ю., Смирнова О.А., Головина О.Г.</copyright-holder><copyright-holder xml:lang="en">Matvienko O.U., Smirnova O.A., Golovina O.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.extrememedicine.ru/jour/article/view/306">https://www.extrememedicine.ru/jour/article/view/306</self-uri><abstract><sec><title>Введение</title><p>Введение. Среди тяжелых осложнений новой коронавирусной инфекции (COVID-19) выделяют артериальные или венозные тромбозы, которые приводят не только к более тяжелому течению заболевания, но и к увеличению летальности. Развитие гиперкоагуляции, предшествующее реализации тромбоза, обусловлено выраженной активацией системы гемостаза, а также появлением в циркуляции микрочастиц (МЧ), которые генерируются активированными клетками крови и увеличивают прокоагулянтную направленность гемостаза. В связи с этим оценка прогностического значения изменений показателей системы гемостаза, связанных с течением и исходом COVID-19, представляет большой интерес.</p></sec><sec><title>Цель</title><p>Цель. Выявить предикторы неблагоприятного исхода новой коронавирусной инфекции на основе оценки параметров, характеризующих состояние системы гемостаза.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовано 163 пациента (78 мужчин и 85 женщин, возраст которых колебался от 35 до 90 лет, медиана возраста — 69 лет) в остром периоде с тяжелым и среднетяжелым течением заболевания. В зависимости от исхода заболевания пациенты были разделены на две группы: группа «выжившие пациенты» (n = 120); группа «умершие пациенты» (n = 43). Проведено исследование показателей плазменного гемостаза (протромбинового теста по Квику, концентрации фибриногена, активированного парциального тромбопластинового времени, активности фактора VIII, ристоцетин-кофакторной активности и содержания фактора Виллебранда, активности протеина С, антитромбина, уровня свободного протеина S), а также оценка характеристик МЧ. Статистическую обработку полученных результатов выполняли с помощью пакета программного обеспечения Statistica 12.0.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с неблагоприятным исходом заболевания получено значимое снижение протромбинового теста (ПТ) по Квику и активности антитромбина, повышение активности фактора Виллебранда, концентрации D-димера и количества тромбоцитарных МЧ. Проведенный анализ чувствительности и специфичности данных параметров позволил рассматривать ПТ по Квику менее 70% (чувствительность и специфичность составили 70 и 74,3% соответственно), уровень D-димера более 800 нг/мл (чувствительность и специфичность — 72 и 75,2% соответственно) и количество тромбоцитарных МЧ более 3,22% (чувствительность и специфичность — 77,8 и 72,7% соответственно) в качестве пороговых значений, ассоциированных с летальным исходом от СOVID-19.</p></sec><sec><title>Выводы</title><p>Выводы. На основании проведенного ROC-анализа получены прогностические модели риска возникновения неблагоприятного исхода COVID-19, сопряженные с изменениями параметров системы гемостаза: концентрации D-димера, ПТ по Квику и количества тромбоцитарных МЧ, которые могут быть использованы в качестве лабораторных предикторов неблагоприятного течения заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Severe complications of the novel coronavirus infection (COVID-19) include arterial or venous thromboses, which not only complicate the disease course but also increase mortality. The development of hypercoagulability, which precedes the occurrence of thrombosis, is associated with a significant activation of the hemostasis system, as well as the appearance of microparticles in circulation. These microparticles, generated by activated blood cells, enhance the procoagulant orientation of hemostasis. In this regard, assessment of the prognostic value of changes in hemostasis system parameters associated with the progression and outcome of COVID-19 represents a relevant research task.</p></sec><sec><title>Objective</title><p>Objective. To identify predictors of adverse outcomes of the novel coronavirus infection based on the assessment of parameters characterizing the state of the hemostasis system.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A total of 163 patients (78 males and 85 females, aged 35–90 years, median age 69 years) were examined during the acute phase of the disease with severe and moderate severity. Depending on the disease outcome, the patients were divided into two groups: the group of survivors (n = 120) and the group of the deceased (n = 43). A study of plasma hemostasis parameters was conducted, including Quick’s prothrombin test, fibrinogen concentration, activated partial thromboplastin time, factor VIII activity, ristocetin cofactor activity, von Willebrand factor content, protein C activity, antithrombin, and free protein S. In addition, the characteristics of microparticles were studied. Statistical processing of the results was performed using the Statistica 12.0 software package.</p></sec><sec><title>Results</title><p>Results. In patients with adverse disease outcomes, a significant decrease in Quick’s prothrombin time (PT) and antithrombin activity was observed, along with an increase in von Willebrand factor activity, D-dimer concentration, and platelet microparticle count. The analysis of sensitivity and specificity of these parameters allowed Quick’s PT less than 70% (sensitivity and specificity were 70% and 74.3%, respectively), D-dimer level more than 800 ng/ml (sensitivity and specificity — 72% and 75.2%, respectively), and platelet MP count more than 3.22% (sensitivity and specificity — 77.8% and 72.7%, respectively) to be considered as threshold values associated with lethal outcome from COVID-19.</p></sec><sec><title>Conclusions</title><p>Conclusions. Based on the conducted ROC analysis, predictive models for the risk of adverse outcomes of COVID-19 associated with changes in hemostasis system parameters were obtained. The parameters of D-dimer concentration, Quick’s prothrombin time, and platelet microparticle count can be used as laboratory predictors of unfavorable disease progression.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неблагоприятный исход</kwd><kwd>COVID-19</kwd><kwd>гиперкоагуляция</kwd><kwd>протромбиновый тест по Квику</kwd><kwd>D-димер</kwd><kwd>тромбоцитарные микрочастицы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adverse outcome</kwd><kwd>COVID-19</kwd><kwd>hypercoagulation</kwd><kwd>Quick’s prothrombin test</kwd><kwd>D-dimer</kwd><kwd>platelet microparticles</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">работа выполнена в рамках государственного задания на 2023–2025 гг. «Разработка новых критериев прогнозирования риска развития отсроченных осложнений у пациентов с заболеваниями системы крови, перенесших COVID-19», № 12305000055-0</funding-statement><funding-statement xml:lang="en">the work was carried out within the framework of the state assignment for 2023–2025 “Development of new criteria for predicting the risk of delayed complications in patients with blood system diseases who have had COVID-19”, No. 12305000055-0</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Галстян ГМ. Коагулопатия при COVID-19. Пульмонология. 2020;30(5):645–57. https://doi.org/10.18093/0869-0189-2020-30-5-645-657</mixed-citation><mixed-citation xml:lang="en">Galstyan GM. Coagulopathy in COVID-19. Pulmonology. 2020;30(5):645–57 (In Russ.). https://doi.org/10.18093/0869-0189-2020-30-5-645-657</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Буланов АЮ, Ройтман ЕВ. Новая коронавирусная инфекция, система гемостаза и проблемы дозирования гепаринов: это важно сказать сейчас. Тромбоз, Гемостаз и Реология. 2020;2:11–8. https://doi.org/10.25555/THR.2020.2.0913</mixed-citation><mixed-citation xml:lang="en">Bulanov AYu, Roitman EV. New coronavirus infection, hemostatic and heparin dosing problems: it is important to say now. Thrombosis, Hemostasis and Rheology. 2020;2:11–8 (In Russ.). https://doi.org/10.25555/THR.2020.2.0913</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лобастов КВ, Порембская ОЯ, Счастливцев ИВ. Эффективность и безопасность применения антитромботической терапии при COVID-19. Амбулаторная Хирургия. 2021;18(2):17–30. https://doi.org/10.21518/1995-1477-2021-18-2</mixed-citation><mixed-citation xml:lang="en">Lobastov KV, Porembskaya OYa, Schastlivtsev IV. Efficiency and safety of antithrombotic therapy in COVID-19. Ambulatory Surgery. 2021;18(2):17–30 (In Russ.). https://doi.org/10.21518/1995-1477-2021-18-2</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Di Minno AD, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Seminars in Thrombosis and Hemostasis. 2020;46(7):763–71. https://doi.org/10.1055/s-0040-1715456</mixed-citation><mixed-citation xml:lang="en">Di Minno AD, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Seminars in Thrombosis and Hemostasis. 2020;46(7):763–71. https://doi.org/10.1055/s-0040-1715456</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Матвиенко ОЮ, Корсакова НЕ, Лернер АА, Шведова ТН, Папаян ЛП. Состояние плазменного звена гемостаза у пациентов с коронавирусной инфекцией, вызванной вирусом SARS-CoV-2. Тромбоз, Гемостаз и Реология. 2020;4:52–6. https://doi.org/10.25555/THR.2020.4.0945</mixed-citation><mixed-citation xml:lang="en">Matvienko OYu, Korsakova NE, Lerner AA, Shvedova TN, Papayan LP. The state of the plasma hemostasis in patients with coronavirus infection caused by the SARS-CoV-2 virus. Thrombosis, Hemostasis and Rheology. 2020;4:52–6 (In Russ.). https://doi.org/10.25555/THR.2020.4.0945</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thrombosis and Haemostasis. 2020;120(12):1642–53. https://doi.org/10.1055/s-0040-1718532</mixed-citation><mixed-citation xml:lang="en">Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thrombosis and Haemostasis. 2020;120(12):1642–53. https://doi.org/10.1055/s-0040-1718532</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кузнецов СИ, Шестаков ЕА, Жибурт ЕБ. Коагулопатия при инфекции COVID-19. Тромбоз, Гемостаз и Реология. 2020;4:31–4. https://doi.org/10.25555/THR.2020.4.0942</mixed-citation><mixed-citation xml:lang="en">Kuznetsov SI, Shestakov EA, Zhiburt EB. Coagulopathy in COVID-19 infection. Thrombosis, Hemostasis and Rheology. 2020;4:31–4 (In Russ.). https://doi.org/10.25555/THR.2020.4.0942</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis. 2020;18(7):1747–51. https://doi.org/10.1111/jth.14854</mixed-citation><mixed-citation xml:lang="en">Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis. 2020;18(7):1747–51. https://doi.org/10.1111/jth.14854</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Момот АП, Царигородцева НО, Федоров ДВ, Бишевский КМ, Вострикова НВ, Климова ЕЕ. Тромбоцитарные микровезикулы и их роль в обеспечении гемостатического потенциала (обзор литературы). Сибирский Научный Медицинский Журнал. 2020;40(2):4–14. https://doi.org/10.15372/SSMJ20200201</mixed-citation><mixed-citation xml:lang="en">Momot AP, Tsarigorodtseva NO, Fedorov DV, Bishevski KM, Vostrikova NV, Klimova EE. Platelet microvesicles and their role in providing hemostatic potential (literature review). Siberian Scientific Medical Journal. 2020;40(2):4–14 (In Russ.). https://doi.org/10.15372/SSMJ20200201</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Зубаиров ДМ, Зубаирова ЛД. Микровезикулы в крови. Функции и их роль в тромбообразовании. М.: ГЭОТАРМедиа; 2009.</mixed-citation><mixed-citation xml:lang="en">Zubairov DM, Zubairova LD. Microvesicles in the blood. Functions and their role in thrombus formation. Moscow: GEOTAR-Media; 2009 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сироткина ОВ, Ермаков АИ, Гайковая ЛБ, Кудлай ДА, Вавилова ТВ. Микрочастицы клеток крови у больных COVID-19 как маркер активации системы гемостаза. Тромбоз, Гемостаз и Реология.2020;4:35–40. https://doi.org/10.25555/THR.2020.4.0943</mixed-citation><mixed-citation xml:lang="en">Sirotkina OV, Ermakov AI, Gaykovaya LB, Kudlay DA, Vavilova TV. Microparticles of blood cells in patients with COVID-19 as a marker of hemostasis activation. Thrombosis, Hemostasis and Rheology. 2020;4:35–40 (In Russ.). https://doi.org/10.25555/THR.2020.4.0943</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease. Journal of Medical Virology. 2021;93(5):3165–75. https://doi.org/10.1002/jmv.26876</mixed-citation><mixed-citation xml:lang="en">Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease. Journal of Medical Virology. 2021;93(5):3165–75. https://doi.org/10.1002/jmv.26876</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Shang K, Bian W, He L, Fan Y, Ren T, et al. Prediction of disease progression in patients with COVID-19 by artificial intelligence assisted lesion quantification. Scientific Reports. 2020;10(1):22083. https://doi.org/10.1038/s41598-020-79097-1</mixed-citation><mixed-citation xml:lang="en">Li Y, Shang K, Bian W, He L, Fan Y, Ren T, et al. Prediction of disease progression in patients with COVID-19 by artificial intelligence assisted lesion quantification. Scientific Reports. 2020;10(1):22083. https://doi.org/10.1038/s41598-020-79097-1</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ozel AS, Altunal LN, Aydin M, Unal M, Cam G, Ozer MC, et al. Clinical characteristics and risk factors associated with severe disease and outcome of patients with COVID-19. Journal of Infection in Developing Countries. 2022;16(3):435–44. https://doi.org/10.3855/jidc.15411</mixed-citation><mixed-citation xml:lang="en">Ozel AS, Altunal LN, Aydin M, Unal M, Cam G, Ozer MC, et al. Clinical characteristics and risk factors associated with severe disease and outcome of patients with COVID-19. Journal of Infection in Developing Countries. 2022;16(3):435–44. https://doi.org/10.3855/jidc.15411</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine. 2020;58(7):1021–8. https://doi.org/10.1515/cclm-2020-0369</mixed-citation><mixed-citation xml:lang="en">Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine. 2020;58(7):1021–8. https://doi.org/10.1515/cclm-2020-0369</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Мищенко ТА, Ермакова ПА, Ермакова АА, Целлер ЛП, Рогожкина ЮА, Вертелецкая МИ и др. Предикторы тяжелого течения новой коронавирусной инфекции (COVID-19): дизайн исследования. Терапевтический Архив. 2022;94(11):1246–51. https://doi.org/10.26442/00403660.2022.11.201402</mixed-citation><mixed-citation xml:lang="en">Mishchenko TA, Ermakova PA, Ermakova AA, Tseller LP, Rogozhkina YA, Verteletskaya MI, et al. Predictors of severe course of new coronavirus infection (COVID-19): study design. Therapeutic Archive. 2022;94(11):1246–51 (In Russ.). https://doi.org/10.26442/00403660.2022.11.201402</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bobcakova A, Petriskova J, Vysehradsky R, Kocan I, Kapustova L, Barnova M, et al. Immune profile in patients with COVID-19: lymphocytes exhaustion markers in relationship to clinical outcome. Frontiers in Cellular and Infection Microbiology. 2021;11:646688. https://doi.org/10.3389/fcimb.2021.646688</mixed-citation><mixed-citation xml:lang="en">Bobcakova A, Petriskova J, Vysehradsky R, Kocan I, Kapustova L, Barnova M, et al. Immune profile in patients with COVID-19: lymphocytes exhaustion markers in relationship to clinical outcome. Frontiers in Cellular and Infection Microbiology. 2021;11:646688. https://doi.org/10.3389/fcimb.2021.646688</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rajpoot A, Mishra M, Banerjee S, Kumar A, Panda PK, Sindhwani G, et al. Predictors of poor outcome in patients with COVID-19 associated respiratory failure: a retrospective observational study. Journal of the Association of Physicians of India. 2023;71(4):11–2.</mixed-citation><mixed-citation xml:lang="en">Rajpoot A, Mishra M, Banerjee S, Kumar A, Panda PK, Sindhwani G, et al. Predictors of poor outcome in patients with COVID-19 associated respiratory failure: a retrospective observational study. Journal of the Association of Physicians of India. 2023;71(4):11–2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oudkerk M, Büller HR, Kuijpers D, Oudkerk SF, van Beek JR. D-Dimer and COVID-19. Radiology. 2020;297(3):343–4. https://doi.org/10.1148/radiol.2020203481</mixed-citation><mixed-citation xml:lang="en">Oudkerk M, Büller HR, Kuijpers D, Oudkerk SF, van Beek JR. D-Dimer and COVID-19. Radiology. 2020;297(3):343–4. https://doi.org/10.1148/radiol.2020203481</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Yan X, Fan Q, Liu X, Liu Z, Zhang Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of Thrombosis and Haemostasis. 2020;18(6):1324–9. https://doi.org/10.1111/jth.14859</mixed-citation><mixed-citation xml:lang="en">Zhang L, Yan X, Fan Q, Liu X, Liu Z, Zhang Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of Thrombosis and Haemostasis. 2020;18(6):1324–9. https://doi.org/10.1111/jth.14859</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Момот ДА, Мамаев АН, Николаева МГ, Момот АП, Кудинов АВ, Неймарк МИ. Анализ возможностей применения нового метода определения уровня D-димера в плазме крови у больных с COVID-19 на госпитальном этапе. Бюллетень Медицинской Науки. 2023;2(30):79–86. https://doi.org/10.31684/25418475-2023-2-79</mixed-citation><mixed-citation xml:lang="en">Momot DA, Mamaev AN, Nikolaeva MG, Momot AP, Kudinov AV, Neimark MI. Advancing plasma D-dimer level determination: an applicability analysis for COVID-19 patients at the hospital stage. Bulletin of Medical Science. 2023;2(30):79–86 (In Russ.). https://doi.org/10.31684/25418475-2023-2-79</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьева НА, Воробьева АИ. Прогностическая значимость Д-димера при COVID-19. Проблемы Стандартизации в Здравоохранении. 2021;5–6:36–42. https://doi.org/10.26347/1607-2502202105-06036-042</mixed-citation><mixed-citation xml:lang="en">Vorobyeva NA, Vorobyeva AI. Predictive value of D-dimer in COVID-19. Health Care Standardization Problems. 2021;5– 6:36–42. https://doi.org/10.26347/1607-2502202105-06036-042</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
